Pharmac has reached a provisional agreement to fund Trikafta, a cystic fibrosis drug which has been found to extend life expentancy by 27 years.
Cystic fibrosis is a terminal condition that affects about 540 people in New Zealand.
Previously, the drug cost patients $330,000 per year, putting it far out of reach for most.
Cystic Fibrosis NZ chief executive Lisa Burns spoke to Corin Dann.
